NHẬN XÉT ĐIỀU TRỊ Ở NGƯỜI BỆNH NỘI TRÚ RỐI LOẠN HỖN HỢP LO ÂU VÀ TRẦM CẢM

Abstract

Objective: To describe the treatment characteristics in inpatient diagnosed with comorbid anxiety and depressive disorder (F41.2) according to the ICD-10 criteria. Method: Cross-sectional description of 75 inpatients treated at the Mental Health Institute - Bach Mai Hospital and Hanoi Mental Hospital, meeting the diagnosis of mixed anxiety and depressive disorder (F41.2) according to ICD-10 diagnostic criteria, from November 2022 to March 2023. Results: 100% of the patients received combination therapy, with the majority (86.7%) receiving a combination of antidepressants, anxiolytics, and antipsychotic. The majority of patients (68.0%) underwent pharmacotherapy combined with relaxation therapy. Sertraline and fluvoxamine were the most commonly prescribed antidepressants (36.0%). Quetiapine was the preferred choice for atypical antipsychotic (69.3%). Diazepam was commonly used during the treatment process (90.7%). Constipation (37.3%) and dry mouth (13.3%) were the most common side effects. After treatment, there was a significant reduction in psychological test scores with p < 0.001. Conclusion: During inpatient treatment, the majority of patients with comorbid anxiety and depressive disorder received multi pharmacology therapy along with relaxation therapy. After 14 days of treatment, overall, patients showed a gradual reduction in depressive symptoms and an improvement in sleep quality.